EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Curriculum Vitae

Personal information

Annemieke Aartsma-Rus

Work experience

Present positions

Since 2015	Professor (Hoogleraar) of Translational Genetics at the Department of Human Genetics, Leiden University Medical Center (LUMC)
Since 2013	Visiting professor at the Institute of Genetic Medicine, Newcastle University, Newcastle, UK

Previous positions

2010 - 2015	Associate professor (UHD) at the Dept of Human Genetics, LUMC
2007 –2010	Assistant Professor, Dept of Human Genetics, LUMC
2007.	Postdoctoral fellow, Dept. of Human Genetics, LUMC
2004.	PhD student, Dept. of Human Genetics, LUMC
2000 (Jan-June)	Research Technician, Biomedical Primate Research Center, Rijswijk, the Netherlands

Education and training

2000	MSc Biomedical Sciences, Leiden University (The Netherlands)
2005	PhD: "Development of an antisense-mediated exon skipping therapy for Duchenne muscular dystrophy. Making sense out of nonsense", supervised by prof dr G.J.B. van Ommen, head of the Department of Human genetics, Leiden University Medical Centre.
2015	University Teaching Qualification (Basis Kwalificatie Onderwijs, an accreditation standard for teaching from Dutch Universities)

Additional information

Publications

H-Index: 57 (ISI Web of Science, cited 12,152 times)

H-Index: 68 (Googlescholar; cited 19,526 times); I10index: 208

H-Index: 60 (Researchgate: research interest score: 6,687.5; citations 14,337, reads 58,521)

Number of first author publications: 49

Number of last author publications: 57

Scientific journal publications

1. Johansson C, Hunt H, Signorelli M, Edfors F, Hober A, Svensson AS, Tegel H, Forstström B, **Aartsma-Rus A**, Niks E,

Spitali P, Uhlén M, Szigyarto CA.: Orthogonal proteomics methods warrant the development of Duchenne muscular dystrophy biomarkers. Clin Proteomics. 2023 Jun 12;20(1):23. doi: 10.1186/s12014-023-09412-1.

2. Cameron D, Abbassi-Daloii T, Heezen LGM, van de Velde NM, Koeks Z, Veeger TTJ, Hooijmans MT, El Abdellaoui S, van Duinen SG, Verschuuren JJGM, van Putten M, **Aartsma-Rus A**, Raz V, Spitali P, Niks EH, Kan HE: Diffusion-tensor magnetic resonance imaging captures increased skeletal muscle fibre diameters in Becker muscular dystrophy. J Cachexia Sarcopenia Muscle. 2023 May 1. doi: 10.1002/jcsm.13242.
3. van Deutekom J, Beekman C, Bijl S, Bosgra S, van den Eijnde R, Franken D, Groenendaal B, Harquouli B, Janson A, Koevoets P, Mulder M, Muilwijk D, Peterburgska G, Querido B, Testerink J, Verheul R, de Visser P, Weij R, **Aartsma-Rus A**, Puoliväli J, Bragge T, O'Neill C, Datson NA. Next Generation Exon 51 Skipping Antisense Oligonucleotides for Duchenne Muscular Dystrophy. Nucleic Acid Ther. 2023 Apr 10. doi: 10.1089/nat.2022.0063
4. Signorelli M, Tsonaka R, **Aartsma-Rus A**, Spitali P.: Multiomic characterization of disease progression in mice lacking dystrophin. PLoS One. 2023 Mar 31;18(3):e0283869. doi: 10.1371/journal.pone.0283869
5. **Aartsma-Rus AM**: The future of exon skipping for Duchenne muscular dystrophy. Hum Gene Ther. 2023 Mar 16. doi: 10.1089/hum.2023.026
6. **Aartsma-Rus A**, De Waele L, Houwen-Opstal S, Kirschner J, Krom YD, Mercuri E, Niks EH, Straub V, van Duyvenvoorde HA, Vroom E.: The Dilemma of Choice for Duchenne Patients Eligible for Exon 51 Skipping The European Experience. J Neuromuscul Dis. 2023 Mar 6. doi: 10.3233/JND-221648
7. Q&A with **Annemieke Aartstma-Rus** on Individualized ASO therapy for rare diseases. Commun Med (Lond). 2023 Feb 28;3(1):27. doi: 10.1038/s43856-023-00255-3.
8. Muntoni F, Signorovitch J, Sajeev G, Lane H, Jenkins M, Dieye I, Ward SJ, McDonald C, Goemans N, Niks EH, Wong B, Servais L, Straub V, Guglieri M, de Groot IJM, Chesshyre M, Tian C, Manzur AY, Mercuri E, **Aartsma-Rus A.**: DMD Genotypes and Motor Function in Duchenne Muscular Dystrophy: A Multi-institution Meta-analysis With Implications for Clinical Trials. Neurology. 2023 Feb 1:10.1212/WNL.0000000000201626. doi: 10.1212/WNL.0000000000201626.
9. **Aartsma-Rus A**, van Roon-Mom W, Lauffer M, Siezen C, Duijndam B, Coenen-de Roo T, Schüle R, Synofzik M, Graessner H.: Development of tailored splice switching oligonucleotides for progressive brain disorders in Europe: development, regulation and implementation considerations. RNA. 2023 Jan 20:rna.079540.122. doi: 10.1261/rna.079540.122.
10. Filonova G, **Aartsma-Rus A.:** Next steps for the optimization of exon therapy for Duchenne muscular dystrophy. Expert Opin Biol Ther. 2023 Jan 21:1-11. doi: 10.1080/14712598.2023.2169070.
11. **Aartsma-Rus A**.: Good news for the mdx mouse community: Improved dystrophin restoration after skipping mouse dystrophin exon 23. Mol Ther Nucleic Acids. 2022 Nov 8;30:355-356. doi: 10.1016/j.omtn.2022.10.009.
12. **Aartsma-Rus A**, van Putten M, Mantuano P, De Luca A.: On the use of D2.B10-Dmdmdx/J (D2.mdx) Versus C57BL/10ScSn-Dmdmdx/J (mdx) Mouse Models for Preclinical Studies on Duchenne Muscular Dystrophy: A Cautionary Note from Members of the TREAT-NMD Advisory Committee on Therapeutics. J Neuromuscul Dis. 2022 Oct 31. doi: 10.3233/JND-221547.
13. Engelbeen S, Pasteuning-Vuhman S, Boertje-van der Meulen J, Parmar R, Charisse K, Sepp-Lorenzino L, Manoharan M, **Aartsma-Rus A,** van Putten M: Efficient Downregulation of Alk4 in Skeletal Muscle After Systemic Treatment with Conjugated siRNAs in a Mouse Model for Duchenne Muscular Dystrophy. Nucleic Acid Ther. 2022 Oct 20. doi: 10.1089/nat.2022.0021.
14. Chey YCJ, Arudkumar J, **Aartsma-Rus A**, Adikusuma F, Thomas PQ. :CRISPR applications for Duchenne muscular dystrophy: From animal models to potential therapies. WIREs Mech Dis. 2022 Jul 31:e1580. doi: 10.1002/wsbm.1580
15. Alqallaf A, Engelbeen S, Palo A, Cutrupi F, Tanganyika-de Winter C, Plomp J, Vaiyapuri S, **Aartsma-Rus A**, Patel K, van Putten M. The therapeutic potential of soluble activin type IIB receptor treatment in a limb girdle muscular dystrophy type 2D mouse model. Neuromuscul Disord. 2022 May;32(5):419-435. doi: 10.1016/j.nmd.2022.03.002.
16. Duan D, Flanigan KM, **Aartsma-Rus A**. Letter by Duan et al Regarding Article, "Therapeutic Exon Skipping Through a CRISPR-Guided Cytidine Deaminase Rescues Dystrophic Cardiomyopathy In Vivo". Circulation. 2022 May 3;145(18):e872-e873. doi: 10.1161/CIRCULATIONAHA.121.058714.
17. **Aartsma-Rus A**, Dooms, M, Le Cam Y, OD Expert Group and Copenhagen Economics: Orphan Medicine Incentives: How to Address the Unmet Needs of Rare Disease Patients by Optimizing the European Orphan Medicinal Product Landscape

Guiding Principles and Policy Proposals by the European Expert Group for Orphan Drug Incentives (OD Expert Group). Frontiers in Pharmacology. 2021 Dec 16. Doi 10.3389/fphar.2021.744532.

18. Evéquoz D, Verhaart IEC, van de Vijver D, Renner W, **Aartsma-Rus A,** Leumann CJ: 7',5'-alpha-bicyclo-DNA: new chemistry for oligonucleotide exon splicing modulation therapy. Nucleic Acids Res. 2021 Dec 2;49(21):12089-12105. doi: 10.1093/nar/gkab1097.
19. **Aartsma-Rus A**, Vroom E, O'Reilly D: The Role of Patient Involvement When Developing Therapies. Nucleic Acid Ther. 2021 Oct 1. doi: 10.1089/nat.2021.0048.
20. Synofzik M, van Roon-Mom WMC, Marckmann G, van Duyvenvoorde HA, Graessner H, Schüle R, **Aartsma-Rus A.:** Preparing n-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in Europe: Genetic, Regulatory, and Ethical Perspectives. Nucleic Acid Ther. 2021 Sep 29. doi: 10.1089/nat.2021.0039. Online ahead of print.
21. Alghamdi F, Al-Tawari A, Alrohaif H, Alshuaibi W, Mansour H, **Aartsma-Rus A** and Mégarbané A: Case Report: The Genetic Diagnosis of Duchenne Muscular Dystrophy in the Middle East. Front. Pediatr., 13 September 2021. https://doi.org/10.3389/fped.2021.716424
22. **Aartsma-Rus A**.: 'N of 1' therapies need a better model. Nat Med. 2021 Jun;27(6):939. doi: 10.1038/s41591-021-01380-z.
23. Tsonaka R, Seyer A, **Aartsma-Rus A**, Spitali P.: Plasma lipidomic analysis shows a disease progression signature in mdx mice. Sci Rep. 2021 Jun 21;11(1):12993. doi: 10.1038/s41598-021-92406-6.
24. Marchal GA, van Putten M, Verkerk AO, Casini S, Putker K, van Amersfoorth SCM, **Aartsma-Rus A**, Lodder EM, Remme CA.: Low human dystrophin levels prevent cardiac electrophysiological and structural remodelling in a Duchenne mouse model. Sci Rep. 2021 May 7;11(1):9779. doi: 10.1038/s41598-021-89208-1.
25. Hammond SM, **Aartsma-Rus A**, Alves S, Borgos SE, Buijsen RAM, Collin RWJ, Covello G, Denti MA, Desviat LR, Echevarría L, Foged C, Gaina G, Garanto A, Goyenvalle AT, Guzowska M, Holodnuka I, Jones DR, Krause S, Lehto T, Montolio M, Van Roon-Mom W, Arechavala-Gomeza V.: Delivery of oligonucleotide-based therapeutics: challenges and opportunities. EMBO Mol Med. 2021 Apr 9;13(4):e13243
26. Signorelli M, Ebrahimpoor M, Veth O, Hettne K, Verwey N, García-Rodríguez R, Tanganyika-deWinter CL, Lopez Hernandez LB, Escobar Cedillo R, Gómez Díaz B, Magnusson OT, Mei H, Tsonaka R, **Aartsma-Rus A**, Spitali P.: Peripheral blood transcriptome profiling enables monitoring disease progression in dystrophic mice and patients. EMBO Mol Med. 2021 Apr 9;13(4)
27. Gravesteijn G, Hack RJ, van Opstal AM, van Eijsden BJ, Middelkoop HAM, Rodriguez Girondo MDM, **Aartsma-Rus A**, van de Grond J, Rutten JW, Lesnik Oberstein SAJ: Eighteen-Year Disease Progression and Survival in CADASIL; J Stroke 2021 Jan;23(1):132-134.
28. Duan D, Goemans N, Takeda S, Mercuri E, **Aartsma-Rus A:** Duchenne muscular dystrophy. Nat Rev Dis Primers. 2021 Feb 18;7(1):13.
29. Alvelos MI, Brüggemann M, Sutandy FR, Juan-Mateu J, Colli ML, Busch A, Lopes M, Castela Â, Aartsma-Rus A, König J, Zarnack K, Eizirik DL. : The RNA-binding profile of the splicing factor SRSF6 in immortalized human pancreatic β-cells. Life Sci Alliance. 2020 Dec 29;4(3):e202000825.
30. Yavas A, Weij R, van Putten M, Kourkouta E, Beekman C, Puoliväli J, Bragge T, Ahtoniemi T, Knijnenburg J, Hoogenboom ME, Ariyurek Y, Aartsma-Rus A, van Deutekom J, Datson N.: Detailed genetic and functional analysis of the hDMDdel52/mdx mouse model. PLoS One. 2020 Dec 23;15(12):e0244215.
31. Hiller M, Geissler M, Janssen G, van Veelen P, **Aartsma-Rus A**, Spitali P.: The mRNA Binding Proteome of Proliferating and Differentiated Muscle Cells. Genomics Proteomics Bioinformatics. 2020 Dec 15:S1672-0229(20)30134-0.
32. Schneider AE, **Aartsma-Rus A**: Developments in reading frame restoring therapy approaches for Duchenne muscular dystrophy. Expert Opin Biol Ther. 2020
33. Verhaart IEC, Cappellari O, Tanganyika-de Winter CL, Plomp JJ, Nnorom S, Wells KE, Hildyard JCW, Bull D, **Aartsma-Rus A**, Wells DJ: Simvastatin Treatment Does Not Ameliorate Muscle Pathophysiology in a Mouse Model for Duchenne Muscular Dystrophy. J Neuromuscul Dis. 2020 3.
34. Lyu P, Yoo KW, Yadav MK, Atala A, **Aartsma-Rus A**, Putten MV, Duan D, Lu B: Sensitive and reliable evaluation of single-cut sgRNAs to restore dystrophin by a GFP-reporter assay. PLoS One. 2020 Sep 24;15(9):e0239468.
35. Passarelli C, Selvatici R, Carrieri A, Di Raimo FR, Falzarano MS, Fortunato F, Rossi R, Straub V, Bushby K, Reza M,

Zharaieva I, D'Amico A, Bertini E, Merlini L, Sabatelli P, Borgiani P, Novelli G, Messina S, Pane M, Mercuri E, Claustres M, Tuffery-Giraud S, **Aartsma-Rus A**, Spitali P, T'Hoen PAC, Lochmüller H, Strandberg K, Al-Khalili C, Kotelnikova E, Lebowitz M, Schwartz E, Muntoni F, Scapoli C, Ferlini A: Tumor Necrosis Factor Receptor SF10A (TNFRSF10A) SNPs Correlate With Corticosteroid Response in Duchenne Muscular Dystrophy. Front Genet. 2020 Jul 3;11:605.

36. García-Rodríguez R, Hiller M, Jiménez-Gracia L, van der Pal Z, Balog J, Adamzek K, **Aartsma-Rus A**, Spitali P: Premature Termination Codons in the DMD Gene Cause Reduced Local mRNA Synthesis. Proc Natl Acad Sci U S A 2020 Jul 2 ebup
37. Kuijper EC, Bergsma AJ, Pijnappel WWMP, **Aartsma-Rus A**: Opportunities and challenges for antisense oligonucleotide therapies..J Inherit Metab Dis. 2020 May 11.
38. Strandberg K, Ayoglu B, Roos A, Reza M, Niks E, Signorelli M, Fasterius E, Pontén F, Lochmüller H, Domingos J, Ala P, Muntoni F, **Aartsma-Rus A**, Spitali P, Nilsson P, Szigyarto CA: Blood-derived biomarkers correlate with clinical progression in Duchenne muscular dystrophy. J Neuromuscul Dis. 2020;7(3):231-246.
39. **Annemieke Aartsma-Rus**. Lancet Neurol. 2020 May;19(5):388.
40. Hechtelt Jonker A, Hivert V, Gabaldo M, Batista L, O'Connor D, **Aartsma-Rus A**, Day S, Sakushima K, Ardigo D. Boosting delivery of rare disease therapies: the IRDiRC Orphan Drug Development Guidebook. .Nat Rev Drug Discov. 2020 Apr 20.
41. Krishnan VS, **Aartsma-Rus A**, Overzier M, Lutz C, Bogdanik L, Grounds MD. Implications of increased S100β and Tau5 proteins in dystrophic nerves of two mdx mouse models for Duchenne muscular dystrophy. Mol Cell Neurosci. 2020 Mar 30:103484.
42. van Putten M, Hmeljak J, **Aartsma-Rus A**, Dowling JJ. Moving neuromuscular disorders research forward: from novel models to clinical studies. Dis Model Mech. 2020 Feb 25;13(2).
43. Willmann R, Lee J, Turner C, Nagaraju K, **Aartsma-Rus A**, Wells DJ, Wagner KR, Csimma C, Straub V, Grounds MD, De Luca A. Improving translatability of preclinical studies for neuromuscular disorders: lessons from the TREAT-NMD Advisory Committee for Therapeutics (TACT). Dis Model Mech. 2020 Feb 7;13(2).
44. **Aartsma-Rus A,** Corey DR. The 10th Oligonucleotide Therapy Approved: Golodirsen for Duchenne Muscular Dystrophy. Nucleic Acid Ther. 2020
45. Tsonaka R, Signorelli M, Sabir E, Seyer A, Hettne K, **Aartsma-Rus A**, Spitali P. Longitudinal metabolomic analysis of plasma enables modeling disease progression in Duchenne muscular dystrophy mouse models. Hum Mol Genet. 2020 Jan 10
46. Hellebrekers DMJ, Doorenweerd N, Sweere DJJ, van Kuijk SMJ, **Aartsma-Rus AM**, Klinkenberg S, Vles JSH, Hendriksen JGM. Longitudinal follow-up of verbal span and processing speed in Duchenne muscular dystrophy. Eur J Paediatr Neurol. 2020 Jan 7
47. Gravesteijn G, Dauwerse JG, Overzier M, Brouwer G, Hegeman I, Mulder AA, Baas F, Kruit MC, Terwindt GM, van Duinen SG, Jost CR, **Aartsma-Rus A**, Lesnik Oberstein SAJ, Rutten JW. Naturally occurring NOTCH3 exon skipping attenuates NOTCH3 protein aggregation and disease severity in CADASIL patients. Hum Mol Genet. 2020 Jan 21.
48. Spitali P, Zaharieva I, Bohringer S, Hiller M, Chaouch A, Roos A, Scotton C, Claustres M, Bello L, McDonald CM, Hoffman EP; CINRG Investigators, Koeks Z, Eka Suchiman H, Cirak S, Scoto M, Reza M, 't Hoen PAC, Niks EH, Tuffery-Giraud S, Lochmüller H, Ferlini A, Muntoni F, **Aartsma-Rus A**. TCTEX1D1 is a genetic modifier of disease progression in Duchenne muscular dystrophy. Eur J Hum Genet. 2020 Jan 2.
49. Krooss S, Werwitzke S, Kopp J, Rovai A, Varnholt D, Wachs AS, Goyenvalle A, **Aartsma-Rus A**, Ott M, Tiede A, Langemeier J, Bohne J. Pathological mechanism and antisense oligonucleotide-mediated rescue of a non-coding variant suppressing factor 9 RNA biogenesis leading to hemophilia B. PLoS Genet. 2020 Apr 8;16(4):e1008690.
50. Signorelli M, Ayoglu B, Johansson C, Lochmüller H, Straub V, Muntoni F, Niks E, Tsonaka R, Persson A, **Aartsma-Rus A**, Nilsson P, Al-Khalili Szigyarto C, Spitali P. Longitudinal serum biomarker screening identifies malate dehydrogenase as candidate prognostic biomarker for Duchenne muscular dystrophy. J Cachexia Sarcopenia Muscle. 2019 Dec 27.
51. Verwey N, Gazzoli I, Krause S, Mamchaoui K, Mouly V, **Aartsma-Rus A.** Antisense-Mediated Skipping of Dysferlin Exons in Control and Dysferlinopathy Patient-Derived Cells. Nucleic Acid Ther. 2019 Dec 23.
52. van Westering TLE, Lomonosova Y, Coenen-Stass AML, Betts CA, Bhomra A, Hulsker M, Clark LE, McClorey G, **Aartsma-Rus A**, van Putten M, Wood MJA, Roberts TC. Uniform sarcolemmal dystrophin expression is required to prevent extracellular microRNA release and improve dystrophic pathology. J Cachexia Sarcopenia Muscle. 2019 Dec 17.

53. Aartsma-Rus A, Watts JK. The Munich Meeting: Medical Maturation, More Mechanisms, and Milasen. Nucleic Acid Ther. 2019 Dec;29(6):302-304.
54. Gravesteijn G, Munting LP, Overzier M, Mulder AA, Hegeman I, Derieppe M, Koster AJ, van Duinen SG, Meijer OC, Aartsma-Rus A, van der Weerd L, Jost CR, van den Maagdenberg AMJM, Rutten JW, Lesnik Oberstein SAJ. Progression and Classification of Granular Osmiophilic Material (GOM) Deposits in Functionally Characterized Human NOTCH3 Transgenic Mice. Transl Stroke Res. 2019 Oct 30
55. Southall NT, Natarajan M, Lau LPL, Jonker AH, Deprez B, Guilliams T, Hunter L, Rademaker CM, Hivert V, Ardigò D; IRDiRC Data Mining and Repurposing Task Force. The use or generation of biomedical data and existing medicines to discover and establish new treatments for patients with rare diseases - recommendations of the IRDiRC Data Mining and Repurposing Task Force. Orphanet J Rare Dis. 2019 Oct 15;14(1):225.
56. **Aartsma-Rus A**, van Putten M. The use of genetically humanized animal models for personalized medicine approaches. Dis Model Mech. 2019 Oct 1;13(2).
57. Patel AM, Wierda K, Thorrez L, van Putten M, De Smedt J, Ribeiro L, Tricot T, Gajjar M, Duelen R, Van Damme P, De Waele L, Goemans N, Tanganyika-de Winter C, Costamagna D, **Aartsma-Rus A**, van Duyvenvoorde H, Sampaolesi M, Buyse GM, Verfaillie CM. Dystrophin deficiency leads to dysfunctional glutamate clearance in iPSC derived astrocytes. Transl Psychiatry. 2019 Aug 21;9(1):200
58. **Aartsma-Rus A**, den Dunnen JT. Phenotype predictions for exon deletions/duplications: A user guide for professionals and clinicians using Becker and Duchenne muscular dystrophy as examples. Hum Mutat. 2019 Jul 29
59. Verhaart IEC and **Aartsma-Rus A**. Therapeutic developments for Duchenne muscular dystrophy. Nat Rev Neurol. 2019 May 30. doi: 10.1038/s41582-019-0203-3.
60. Verhaart IEC, van de Vijver D, Boertje-van der Meulen JW, Putker K, Adamzek K, **Aartsma-Rus A**, van Putten M. A modified diet does not ameliorate muscle pathology in a mouse model for Duchenne muscular dystrophy. PLoS One. 2019 Apr 24;14(4):e0215335.
61. **Aartsma-Rus A**, Krieg AM. Advancing Nucleic Acid Therapeutics by Setting Uniform Standards for Experimental Controls. Nucleic Acid Ther. 2019 Apr 9.
62. Van Putten M, Putker K, Overzier M, Adamzek WA, Pasteuning-Vuhman S, Plomp JJ, **Aartsma-Rus A**. Natural disease history of the D2 -mdx mouse model for Duchenne muscular dystrophy. FASEB J. 2019 Apr 1
63. Olie CS, Riaz M, Konietzny R, Charles PD, Pinto-Fernandez A, Kiełbasa SM, **Aartsma-Rus A**, Goeman JJ, Kessler BM, Raz V. Deacetylation Inhibition Reverses PABPN1-Dependent Muscle Wasting. iScience. 2019 Jan 22;12:318-332.
64. van Putten M, Tanganyika-de Winter C, Bosgra S and **Aartsma-Rus A**. Nonclinical Exon Skipping Studies with 2'-O-Methyl Phosphorothioate Antisense Oligonucleotides in mdx and mdx-utrn-/- Mice Inspired by Clinical Trial Results. Nucleic Acid Ther. 2019 Jan 23.
65. Gravesteijn G, Rutten JW, Verberk IMW, Böhringer S, Liem MK, van der Grond J, **Aartsma-Rus A**, Teunissen CE, Lesnik Oberstein SAJ. Serum Neurofilament light correlates with CADASIL disease severity and survival. Ann Clin Transl Neurol.2018 Nov 20;6(1):46-56.
66. **Aartsma-Rus A**, Morgan J, Lonkar P, Neubert H, Owens J, Binks M, Montolio M, Phadke R, Datson N, Van Deutekom J, Morris GE, Rao VA, Hoffman EP, Muntoni F, Arechavala-Gomeza V. Report of a TREAT-NMD/World Duchenne Organisation Meeting on Dystrophin Quantification Methodology. J Neuromuscul Dis. 2019 Jan 2.
67. **Aartsma-Rus A**, Hegde M, Ben-Omran T, Buccella F, Ferlini A, Gallano P, Howell RR, Leturcq F, Martin AS, Potulska-Chromik A, Saute JA, Schmidt WM, Sejersen T, Tuffery-Giraud S, Uyguner ZO, Witcomb LA, Yau S, Nelson SF. Evidence-Based Consensus and Systematic Review on Reducing the Time to Diagnosis of Duchenne Muscular Dystrophy. J Pediatr. 2019 Jan;204:305-313.e14.
68. **Aartsma-Rus A**, Goemans N. A Sequel to the Eteplirsen Saga: Eteplirsen Is Approved in the United States but Was Not Approved in Europe. Nucleic Acid Ther. 2018 Dec 11.
69. Kogelman B, Putker K, Hulsker M, Winter CT, van der Weerd L, **Aartsma-Rus A**, van Putten M. Voluntary exercise improves muscle function and does not exacerbate muscle and heart pathology in aged Duchenne muscular dystrophy mice. J Mol Cell Cardiol. 2018 Oct 15.
70. Gordish-Dressman H, Willmann R, Dalle Pazze L, Kreibich A, van Putten M, Heydemann A, Bogdanik L, Lutz C, Davies K,

Demonbruen AR, Duan D, Elsey D, Fukada SI, Girgenrath M, Patrick Gonzalez J, Grounds MD, Nichols A, Partridge T, Passini M, Sanarica F, Schnell FJ, Wells DJ, Yokota T, Young CS, Zhong Z, Spurney C, Spencer M, De Luca A, Nagaraju K, **Aartsma-Rus A**. "Of Mice and Measures": A Project to Improve How We Advance Duchenne Muscular Dystrophy Therapies to the Clinic. J Neuromuscul Dis. 2018 Sep 3.

71. Hiller M, Spitali P, Datson N, **Aartsma-Rus A**. Exon 51 Skipping Quantification by Digital Droplet PCR in del52hDMD/mdx Mice. Methods Mol Biol. 2018;1828:249-262.
72. Hiller M, Falzarano MS, Garcia-Jimenez I, Sardone V, Verheul RC, Popplewell L, Anthony K, Ruiz-Del-Yerro E, Osman H, Goeman JJ, Mamchaoui K, Dickson G, Ferlini A, Muntoni F, Aartsma-Rus A, Arechavala-Gomeza V, Datson NA, Spitali P. A multicenter comparison of quantification methods for antisense oligonucleotide-induced DMD exon 51 skipping in Duchenne muscular dystrophy cell cultures. PLoS One. 2018 Oct 2;13(10):e0204485.
73. **Aartsma-Rus A**, Arechavala-Gomeza V. Why dystrophin quantification is key in the eteplirsen saga. Nat Rev Neurol. 2018 Aug;14(8):454-456
74. **Aartsma-Rus A**, Mercuri E, Vroom E, Balabanov P. Meeting report of the "Regulatory Exchange Matters" session at the 5th International TREAT-NMD Conference: Lessons in communication: How an early dialogue between patients, regulators and academics can further therapy development for neuromuscular disorders Freiburg, Germany, 27-29 November 2017. Neuromuscul Disord. 2018 Apr 20.
75. Pasteuning-Vuhman S, Putker K, Tanganyika-de Winter CL, Boertje-van der Meulen JW, van Vliet L, Overzier M, Plomp JJ, **Aartsma-Rus A**, van Putten M. Natural disease history of the dy2J mouse model of laminin α2 (merosin)-deficient congenital muscular dystrophy. PLoS One. 2018 May 15;13(5):e0197388.
76. Spitali P, Hettne K, Tsonaka R, Charrout M, van den Bergen J, Koeks Z, Kan HE, Hooijmans MT, Roos A, Straub V, Muntoni F, Al-Khalili-Szigyarto C, Koel-Simmelink MJA, Teunissen CE, Lochmüller H, Niks EH, **Aartsma-Rus A**. Tracking disease progression non-invasively in Duchenne and Becker muscular dystrophies. J Cachexia Sarcopenia Muscle. 2018 Apr 16.
77. van der Pijl EM, van Putten M, Niks EH, Verschuuren JJGM, **Aartsma-Rus A**, Plomp JJ. Low dystrophin levels are insufficient to normalize the neuromuscular synaptic abnormalities of mdx mice. Neuromuscul Disord. 2018 Mar 6.
78. de Bruin D, Bossert N, Aartsma-Rus A, Bouwmeester D. Measuring DNA hybridization using fluorescent DNA-stabilized silver clusters to investigate mismatch effects on therapeutic oligonucleotides. J Nanobiotechnology. 2018 Apr 6;16(1):37.
79. Kogelman B, Khmelinskii A, Verhaart I, Vliet LV, Bink DI, Aartsma-Rus A, Putten MV, Weerd LV. Influence of full-length dystrophin on brain volumes in mouse models of Duchenne muscular dystrophy. PLoS One. 2018 Mar 30;13(3):e0194636.
80. Lochmüller H, Badowska DM, Thompson R, Knoers NV, **Aartsma-Rus A**, Gut I, Wood L, Harmuth T, Durudas A, Graessner H, Schaefer F, Riess O; RD-Connect consortium; NeurOmics consortium; EURenOmics consortium. RD-Connect, NeurOmics and EURenOmics: collaborative European initiative for rare diseases. Eur J Hum Genet. 2018 Feb 27.
81. van Putten M, **Aartsma-Rus A**, Grounds MD, Kornegay JN, Mayhew A, Gillingwater TH, Takeda S, Rüegg MA, De Luca A, Nagaraju K, Willmann R. Update on Standard Operating Procedures in Preclinical Research for DMD and SMA Report of TREAT-NMD Alliance Workshop, Schiphol Airport, 26 April 2015, The Netherlands. J Neuromuscul Dis. 2018;5(1):29-34.
82. Veltrop M, van Vliet L, Hulsker M, Claassens J, Brouwers C, Breukel C, van der Kaa J, Linssen MM, den Dunnen JT, Verbeek S, **Aartsma-Rus A**, van Putten M. A dystrophic Duchenne mouse model for testing human antisense oligonucleotides. PLoS One. 2018 Feb 21;13(2):e0193289.
83. Spitali P, Hettne K, Tsonaka R, Sabir E, Seyer A, Hemerik JBA, Goeman JJ, Picillo E, Ergoli M, Politano L, **Aartsma-Rus A.** Cross-sectional serum metabolomics study of multiple forms of muscular dystrophy. J Cell Mol Med. 2018 Feb 14.
84. Willmann R, Buccella F, De Luca A, Grounds MD; 227th ENMC workshop study group. 227(th) ENMC International Workshop:: Finalizing a plan to guarantee quality in translational research for neuromuscular diseases Heemskerk, Netherlands, 10-11 February 2017. Neuromuscul Disord. 2018 Feb;28(2):185-192.
85. Lourbakos A, Yau N, de Bruijn P, Hiller M, Kozaczynska K, Jean-Baptiste R, Reza M, Wolterbeek R, Koeks Z, Ayoglu B, de Klerk D, Campion G, Zaharieva I, Nadarajah VD, Nilsson P, Al-Khalili Szigyarto C, Muntoni F, Lochmüller H, Verschuuren JJ, Goemans N, Tulinius M, Niks EH, de Kimpe S, **Aartsma-Rus A**, 't Hoen PAC, Spitali P. Evaluation of serum MMP-9 as predictive biomarker for antisense therapy in Duchenne. Sci Rep. 2017 Dec 20;7(1):17888.
86. **Aartsma-Rus A**. Genetic therapies for spinal muscular atrophy type 1. Lancet Neurol. 2017 Dec 8. pii: S1474-

4422(17)30436-2.

87. **Aartsma-Rus A**, Ferlini A, McNally EM, Spitali P, Sweeney HL; workshop participants. 226(th) ENMC International Workshop:: Towards validated and qualified biomarkers for therapy development for Duchenne muscular dystrophy 20-22 January 2017, Heemskerk, The Netherlands. Neuromuscul Disord. 2017 Oct 26.
88. Badrising UA, Tsonaka R, Hiller M, Niks EH, Evangelista T, Lochmüller H,Verschuuren JJ, **Aartsma-Rus A**, Spitali P. Cytokine Profiling of Serum Allows Monitoring of Disease Progression in Inclusion Body Myositis. J Neuromuscul Dis. 2017;4(4):327-335.
89. Jirka SMG, 't Hoen PAC, Diaz Parillas V, Tanganyika-de Winter CL, Verheul RC, Aguilera B, de Visser PC, **Aartsma-Rus AM**. Cyclic Peptides to Improve Delivery and Exon Skipping of Antisense Oligonucleotides in a Mouse Model for Duchenne Muscular Dystrophy. Mol Ther. 2017 Oct 12.
90. Doorenweerd N, Mahfouz A, van Putten M, Kaliyaperumal R, T' Hoen PAC, Hendriksen JGM, **Aartsma-Rus A**, Verschuuren JJGM, Niks EH, Reinders MJT, Kan HE, Lelieveldt BPF. Timing and localization of human dystrophin isoform expression provide insights into the cognitive phenotype of Duchenne muscular dystrophy. Sci Rep. 2017 Oct 3;7(1):12575.
91. Pasteuning-Vuhman S, Putker K, Tanganyika-de Winter CL, Boertje-van der Meulen JW, van Vliet L, Overzier M, Plomp JJ**, Aartsma-Rus A**, van Putten M. Natural disease history of mouse models for limb girdle muscular dystrophy types 2D and 2F. PLoS One. 2017 Aug 10;12(8):e0182704.
92. **Aartsma-Rus A**, Straub V, Hemmings R, Haas M, Schlosser-Weber G, Stoyanova-Beninska V, Mercuri E, Muntoni F, Sepodes B, Vroom E, Balabanov P. Development of Exon Skipping Therapies for Duchenne Muscular Dystrophy: A Critical Review and a Perspective on the Outstanding Issues. Nucleic Acid Ther. 2017 Aug 10.
93. Leary R, Oyewole AO, Bushby K, **Aartsma-Rus A**. Translational Research in Europe for the Assessment and Treatment for Neuromuscular Disorders (TREAT-NMD). Neuropediatrics. 2017 Jul 6.
94. Verhaart IEC, Robertson A, Wilson IJ, **Aartsma-Rus A**, Cameron S, Jones CC, Cook SF, Lochmüller H. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. Orphanet J Rare Dis. 2017 Jul 4;12(1):124.
95. **Aartsma-Rus A**. FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides. Nucleic Acid Ther. 2017 Apr;27(2):67-69.
96. **Aartsma-Rus A,** Balabanov P, Binetti L, Haas M, Haberkamp M, Mitchell J, Rosa MM, Muntoni F, Finkel R, Mercuri E. Stakeholder collaboration for spinal muscular atrophy therapy development. Lancet Neurol. 2017 Apr;16(4):264
97. Godfrey C, Desviat LR, Smedsrød B, Piétri-Rouxel F, Denti MA, Disterer P, Lorain S, Nogales-Gadea G, Sardone V, Anwar R, El Andaloussi S, Lehto T, Khoo B, Brolin C, van Roon-Mom WM, Goyenvalle A, **Aartsma-Rus A**, Arechavala-Gomeza V. Delivery is key: lessons learnt from developing splice-switching antisense therapies. EMBO Mol Med. 2017 Mar 13.
98. van Spreeuwel AC, Bax NA, van Nierop BJ, **Aartsma-Rus A**, Goumans MT, Bouten CV. Mimicking Cardiac Fibrosis in a Dish: Fibroblast Density Rather than Collagen Density Weakens Cardiomyocyte Function. J Cardiovasc Transl Res. 2017 Mar 9
99. Niks E, **Aartsma-Rus A**. Exon skipping: a first in class strategy for Duchenne muscular dystrophy. Expert Opin Biol Ther. 2016 epub Dec 12.
100. **Aartsma-Rus A**, Krieg AM. FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga. Nucleic Acid Ther. 2016 epub Dec 8.
101. Bremer J, Bornert O, Nyström A, Gostynski A, Jonkman MF, **Aartsma-Rus A**, van den Akker PC, Pasmooij AM. Antisense Oligonucleotide-mediated Exon Skipping as a Systemic Therapeutic Approach for Recessive Dystrophic Epidermolysis Bullosa. Mol Ther Nucleic Acids. 2016 Oct 18;5(10):e379.
102. Bello L, Flanigan KM, Weiss RB; United Dystrophinopathy Project., Spitali P, **Aartsma-Rus A**, Muntoni F, Zaharieva I, Ferlini A, Mercuri E, Tuffery-Giraud S, Claustres M, Straub V, Lochmüller H, Barp A, Vianello S, Pegoraro E, Punetha J, Gordish-Dressman H, Giri M, McDonald CM, Hoffman EP; Cooperative International Neuromuscular Research Group.. Association Study of Exon Variants in the NF-κB and TGFβ Pathways Identifies CD40 as a Modifier of Duchenne Muscular Dystrophy. Am J Hum Genet. 2016 Oct 12. pii: S0002-9297(16)30383-4. doi: 10.1016/j.ajhg.2016.08.023.
103. Pasteuning-Vuhman S, Boertje-van der Meulen J, van Putten M, Overzier M, Ten Dijke P, Kiełbasa SM, Arindrarto W, Wolterbeek R, Lezhnina KV, Ozerov IV, Aliper AM, Hoogaars WM, **Aartsma-Rus A**, Loomans CJ. New

function of the myostatin/activin type I receptor (ALK4) as a mediator of muscle atrophy and muscle regeneration. FASEB J. 2016 Oct 12.

104. Lucassen EA, Coomans CP, van Putten M, de Kreij SR, van Genugten JH, Sutorius RP, de Rooij KE, van der Velde M, Verhoeve SL, Smit JW, Löwik CW, Smits HH, Guigas B, **Aartsma-Rus A**, Meijer JH. Environmental 24-hr Cycles Are Essential for Health. Curr Biol. 2016 Jul 25;26(14):1843-53.
105. Bornert O, Peking P, Bremer J, Koller U, van den Akker PC, **Aartsma-Rus A**, Pasmooij AM, Murauer EM, Nyström A. RNA-based therapies for genodermatoses. Exp Dermatol. 2016 epub Jul 4
106. Straub V, Balabanov P, Bushby K, Ensini M…..Haas M, Vroom E and **Aartsma-Rus A**: Stakeholder cooperation to overcome challenges in orphan medicine development: the example of Duchenne muscular dystrophy. Lancet Neur. 2016 15(8):882-890
107. Remmelink E, **Aartsma-Rus A**, Smit AB, Verhage M, Loos M, van Putten M: Cognitive flexibility deficits in a mouse model for the absence of full-length dystrophin. Genes Brain Behav. 2016 May 24.
108. van der Pijl EM, van Putten M, Niks EH, Verschuuren JJ, **Aartsma-Rus A**, Plomp JJ: Characterization of neuromuscular synapse function abnormalities in multiple Duchenne muscular dystrophy mouse models. Eur J Neurosci. 2016 Apr 2.
109. Rutten JW, Dauwerse HG, Peters DJ, Goldfarb A, Venselaar H, Haffner C, van Ommen GB, **Aartsma-Rus A**, Lesnik Oberstein SA: Therapeutic NOTCH3 cysteine correction in CADASIL using exon skipping: in vitro proof of concept. Brain. 2016 Feb 19.
110. **Aartsma-Rus A**. New Momentum for the Field of Oligonucleotide Therapeutics. Mol Ther. 2016 Feb;24(2):193-4.
111. Hulsker M, Verhaart I, van Vliet L, Aartsma-Rus A and van Putten M: Accurate Dystrophin Quantificationin Mouse Tissue; Identification of New and Evaluation of Existing Methods. JND 2016 Jan 27
112. **Aartsma-Rus A**, Ginjaar IB and Bushby K: The importance of genetic diagnosis for Duchenne muscular dystrophy. J Med Genet. 2016 Jan 11.
113. Rutten JW, Klever RR, Hegeman IM, Poole DS, Dauwerse HG, Broos LA, Breukel C, **Aartsma-Rus A**, Verbeek JS, van der Weerd L, van Duinen SG, van den Maagdenberg AM, Lesnik Oberstein SA: The NOTCH3 score: a pre-clinical CADASIL biomarker in a novel human genomic NOTCH3 transgenic mouse model with early progressive vascular NOTCH3 accumulation. Acta Neuropathol Commun. 2015 Dec 29;3(1):89.
114. Oonk S, Spitali P, Hiller M, Switzar L, Dalebout H, Calissano M, Lochmüller H, **Aartsma-Rus A**, Hoen PA and van der Burgt YE: Comparative mass spectrometric and immunoassay-based proteome analysis in serum of Duchenne muscular dystrophy patients. Proteomics Clin Appl. 2015, epub Dec 17.
115. Gazzoli I, Pulyakhina I, Verwey NE, Ariyurek Y, Laros JF, 't Hoen PA and **Aartsma-Rus A**: Non-sequential and multi-step splicing of the dystrophin transcript. RNA Biol. 2015 epub Dec 15.
116. Jirka SM, Tanganyika-de Winter CL, Boertje-van der Meulen JW, van Putten M, Hiller M, Vermue R, de Visser PC, Aartsma-Rus A. Evaluation of 2'-Deoxy-2'-fluoro Antisense Oligonucleotides for Exon Skipping in Duchenne Muscular Dystrophy. Mol Ther Nucleic Acids. 2015 Dec 1;4:e265.
117. Pulyakhina I, Gazzoli I, 't Hoen PA, Verwey N, den Dunnen JT, Aartsma-Rus A, Laros JF. SlicePie: a novel analytical approach for the detection of alternative, non-sequential and recursive splicing. Nucleic Acids Res. 2015 Oct 7.
118. Switzar L, Nicolardi S, Rutten JW, Oberstein SA, Aartsma-Rus A, van der Burgt YE. In-Depth Characterization of Protein Disulfide Bonds by Online Liquid Chromatography-Electrochemistry-Mass Spectrometry. J Am Soc Mass Spectrom. 2015 Sep 14.
119. Kinnett K, Rodger S, Vroom E, Furlong P, **Aartsma-Rus A** and Bushby K: Imperatives for DUCHENNE MD: a Simplified Guide to Comprehensive Care for Duchenne Muscular Dystrophy. PLoS Curr. 2015 epub Aug 7
120. Jirka S and **Aartsma-Rus A**. An update on RNA-targeting therapies for neuromuscular disorders. Curr Opin Neurol. 2015 epub Aug 14.
121. Guiraud S, **Aartsma-Rus A**, Vieira NM, Davies KE, van Ommen GJ, Kunkel LM. The Pathogenesis and Therapy of Muscular Dystrophies. Annu Rev Genomics Hum Genet. 2015 Jun 4. (Epub)
122. Van den Bergen J, **Aartsma-Rus A**. Response to: Studying the role of dystrophin-associated proteins in influencing Becker muscular dystrophy disease severity. Neuromuscul Disord. 2015 Jun;25(6):530-1.

123. Gramlich M, Pane LS, Zhou Q, Chen Z, Murgia M, Schötterl S, Goedel A, Metzger K, Brade T, Parrotta E, Schaller M, Gerull B, Thierfelder L, **Aartsma-Rus A**, Labeit S, Atherton JJ, McGaughran J, Harvey RP, Sinnecker D, Mann M, Laugwitz KL, Gawaz MP, Moretti A: Antisense-mediated exon skipping: a therapeutic strategy for titin-based dilated cardiomyopathy. EMBO Mol Med. 2015 epub Mar 9.
124. van den Bergen JC, Wokke BH, Hulsker MA, Verschuuren JJ, **Aartsma-Rus A**: Studying the role of dystrophin-associated proteins in influencing Becker muscular dystrophy disease severity. Neuromuscul Disord. 2015;25(3):231-7.
125. Bladen CL, Salgado D, Monges S, Foncuberta ME, Kekou K, Kosma K, Dawkins H, Lamont L…, **Aartsma-Rus A**, Beroud C and Lochmüller H. The TREAT-NMD DMD Global database: Analysis of More Than 7000 Duchenne Muscular Dystrophy Mutations. Hum Mutat. 2015 epub Jan 21
126. Arechavala-Gomeza V, Khoo B, Aartsma-Rus A. Splicing modulation therapy in the treatment of genetic diseases. Appl Clin Genet. 2014 ;7:245-52.
127. van den Bergen JC, Hiller M, Böhringer S, Vijfhuizen L, Ginjaar HB, Chaouch A, Bushby K, Straub V, Scoto M, Cirak S, Humbertclaude V, Claustres M, Scotton C, Passarelli C, Lochmüller H, Muntoni F, Tuffery-Giraud S, Ferlini A, **Aartsma-Rus A**, Verschuuren JJ, 't Hoen PA, Spitali P: Validation of genetic modifiers for Duchenne muscular dystrophy: a multicentre study assessing SPP1 and LTBP4 variants. J Neurol Neurosurg Psychiatry. 2014 Dec 4 epub
128. van Putten M, Young C, van den Berg S, Pronk A, Hulsker M, Karnaoukh TG, Vermue R, van Dijk KW, de Kimpe S and **Aartsma-Rus A**: Preclinical Studies on Intestinal Administration of Antisense Oligonucleotides as a Model for Oral Delivery for Treatment of Duchenne Muscular Dystrophy. Mol Ther Nucleic Acids. 2014; 3:e211.
129. Lynn S, **Aartsma-Rus A,** Bushby K, Furlong P, Goemans N, De Luca A, Mayhew A, McDonald C, Mercuri E, Muntoni F, Pohlschmidt M, Verschuuren J, Voit T, Vroom E, Wells DJ, Straub V: Measuring clinical effectiveness of medicinal products for the treatment of Duchenne muscular dystrophy. Neuromuscul Disord. 2014 epub Sept 11.
130. Vojinovic D, Adams HH, van der Lee SJ, Ibrahim-Verbaas CA, Brouwer R, van den Hout MC, Oole E, van Rooij J, Uitterlinden A, Hofman A, van IJcken WF, **Aartsma-Rus A**, van Ommen GB, Ikram MA, van Duijn CM and Amin N. The dystrophin gene and cognitive function in the general population. Eur J Hum Genet. 2014 (epub Sep 17).
131. **Aartsma-Rus A**, Ferlini A, Goemans N, Pasmooij AM, Wells DJ Dr, Bushby K, Vroom E, Balabanov P: Translational and regulatory challenges for exon skipping therapies. Statement paper based on a BM1207 COST Action meeting involving patient representatives, clinicians, preclinical scientists and regulators. Hum Gene Ther. 2014 (epub Sep 3).
132. **Aartsma-Rus A**, Ferlini A, Vroom E: Biomarkers and surrogate endpoints in Duchenne: Meeting report. Neuromuscul Disord. 2014;24:743-5.
133. **Aartsma-Rus A**: Dystrophin quantification in clinical trials. JND. 2014; 1: 41-53.
134. Ayoglu B, Chaouch A, Lochmüller H, Politano L, Bertini E, Spitali P, Hiller M, Niks E, Gualandi F, Pontén F, Bushby K, **Aartsma-Rus A**, Schwartz E, Le Priol Y, Straub V, Uhlén M, Cirak S, 't Hoen PA, Muntoni F, Ferlini A, Schwenk JM, Nilsson P, Al-Khalili Szigyarto C. Affinity proteomics within rare diseases: a BIO-NMD study for blood biomarkers of muscular dystrophies. EMBO Mol Med. 2014 epub Jun 11
135. **Aartsma-Rus A** and van Putten M: Assessing functional performance in the mdx mouse model. J Vis Exp. 2014, epub Mar 27 (85)
136. Kemaladewi DU, Pasteuning S, van der Meulen JW, van Heiningen SH, van Ommen GJ, Ten Dijke P, **Aartsma-Rus A**, 't Hoen PA, Hoogaars WM: Targeting TGF-β Signaling by Antisense Oligonucleotide-mediated Knockdown of TGF-β Type I Receptor. Mol Ther Nucleic Acids. 2014; 3:e156.
137. Wokke BH, van den Bergen JC, Versluis MJ, Niks EH, Milles J, Webb AG, van Zwet EW, **Aartsma-Rus A**, Verschuuren JJ and Kan HE: Quantitative MRI and strength measurements in the assessment of muscle quality in Duchenne muscular dystrophy. Neuromuscul Disord. 2014; 24: 409-16.
138. Tremblay JP, **Aartsma-Rus A**, Bogdanove A, Ferreira MB, Bueren J and Huard J: Development of a web course on gene therapy by the international consortium of gene therapy. Mol Ther. 2014; 22: 482.
139. Verhaart IE, van Vliet-van den Dool L, Sipkens JA, de Kimpe SJ, Kolfschoten IG, van Deutekom JC, Liefaard L, Ridings JE, Hood SR and **Aartsma-Rus A**: The Dynamics of Compound, Transcript, and Protein Effects After Treatment With 2OMePS Antisense Oligonucleotides in mdx Mice. Mol Ther Nucleic Acids. 2014; 18: e148.
140. **Aartsma-Rus A**: Antisense-mediated exon skipping: networking to meet opportunities and to overcome challenges. Nucleic

Acid Ther 2014; 24:1-3.
141. Veltrop M and **Aartsma-Rus A**. Antisense-mediated exon skipping: Taking advantage of a trick from Mother Nature to treat rare genetic diseases. Exp Cell Res. 2014; 325: 50-55.
142. Raz V, Buijze H, Raz Y, Verwey N, Anvar SY, **Aartsma-Rus A** and van der Maarel SM: A Novel Feed-Forward Loop between ARIH2 E3-Ligase and PABPN1 Regulates Aging-Associated Muscle Degeneration. Am J Pathol. 2014; 184: 1119-31.
143. van Putten M, van der Pijl EM, Hulsker M, Verhaart IE, Nadarajah VD, van der Weerd L and **Aartsma-Rus A**: Low dystrophin levels in heart can delay heart failure in mdx mice. J Mol Cell Cardiol. 2014; 69: 17-23.
144. Martin FC, Hiller M, Spitali P, Oonk S, Dalebout H, Palmblad M, Chaouch A, Guglieri M, Straub V, Lochmüller H, Niks EH, Verschuuren JJ, **Aartsma-Rus A**, Deelder AM, van der Burgt YE, 't Hoen PA: Fibronectin is a serum biomarker for Duchenne muscular dystrophy. Proteomics Clin Appl. 2014; 8: 269-78
145. Karkampouna S, Kruithof BP, Kloen P, Obdeijn MC, van der Laan AM, Tanke HJ, Kemaladewi DU, Hoogaars WM, 't Hoen PA, **Aartsma-Rus A**, Clark IM, Ten Dijke P, Goumans MJ, Kruithof-de Julio M: Novel Ex Vivo Culture Method for the Study of Dupuytren's Disease: Effects of TGFβ Type 1 Receptor Modulation by Antisense Oligonucleotides. Mol Ther Nucleic Acids. 2014; 3: e142
146. Jirka SM, Heemskerk H, Tanganyika-de Winter CL, Muilwijk D, Pang KH, de Visser PC, Janson A, Karnaoukh TG, Vermue R, 't Hoen PA, van Deutekom JC, Aguilera B and **Aartsma-Rus A**: Peptide Conjugation of 2'-O-methyl Phosphorothioate Antisense Oligonucleotides Enhances Cardiac Uptake and Exon Skipping in *mdx* Mice. Nucleic Acid Ther 2014; 24: 25-36.
147. Evers MM, Tran HD, Zalachoras I, Meijer OC, den Dunnen JT, van Ommen GJ, **Aartsma-Rus A**, van Roon-Mom WM: Preventing Formation of Toxic N-Terminal Huntingtin Fragments Through Antisense Oligonucleotide-Mediated Protein Modification. Nucleic Acid Ther. 2014; 24: 4-12.
148. Van den Bergen JC, Schade van Westrum SM, Dekker L, van der Kooi AJ, Straathof CS, **Aartsma-Rus A**, Verschuuren JJGM and Ginjaar HB: The clinical characterization of Becker patients with various in-frame deletions predicts favorable outcome for exon skipping therapy. J Neurol Neurosurg and Psych 2014; 85: 92-8.
149. van den Bergen JC, Wokke BH, Janson AA, van Duinen SG, Hulsker MA, Ginjaar HB, van Deutekom JC, **Aartsma-Rus A**, Kan HE, Verschuuren JJ: Dystrophin levels and clinical severity in Becker muscular dystrophy patients. J Neurol Neurosurg Psychiatry. 2014; 85: 747-53
150. Spitali P, Grumati P, Hiller M, Chrisam M, **Aartsma-Rus A**, Bonaldo P: Autophagy is Impaired in the Tibialis Anterior of Dystrophin Null Mice. PLoS Curr MD. 2013 epub Nov 22, 5
151. Veltrop M, van der Kaa J, Claassens J, van Vliet L, Verbeek S and **Aartsma-Rus A**: Generation of embryonic stem cells and mice for Duchenne research. PLoS Curr MD 2013 Sep 10, 5
152. Spitali P, van den Bergen JC, Verhaart IEC, Wokke B, Janson AM, van den Eijnde R, den Dunnen JT, Laros JF, Verschuuren JJGM, ‘t Hoen PAC and **Aartsma-Rus A**: DMD transcript imbalance determines dystrophin levels. FASEB J 2013; 27: 4909-16.
153. De Brouwer AP, Nabuurs SB, Verhaart IE, Oudakker AR, Hordijk R, Yntema HG…..**Aartsma-Rus** A, Hamel BC, van Bokhoven H and Kleefstra T: A 3-base pair deletion, c.9711_9713del, in DMD results in intellectual disability without muscular dystrophy. Eur J Hum Genet 2014; 22: 480-5.
154. **Aartsma-Rus A** and Muntoni F: 194th ENMC international workshop. 3rd ENMC workshop on exon skipping: Towards clinical application of antisense-mediated exon skipping for Duchenne muscular dystrophy 8-10 December 2012, Naarden, the Netherlands. Neuromusc Disord 2013; 23: 934-44.
155. Shi S, Cai J, de Gorter DJJ, Sanchez Duffhues G, Kemaladewi DU, Hoogaars WM, **Aartsma-Rus A**, ‘t Hoen PAC, ten Dijke P: Antisense-Oligonucleotide Mediated Exon Skipping in Activin-Receptor-Like Kinase 2: Inhibiting the Receptor That Is Overactive in Fibrodysplasia Ossificans Progressiva. Plos One 2013; e69096.
156. Dick E, Kalra S, Anderson D, George V, Ritson M, Laval S, Barresi R, **Aartsma-Rus A**, Lochmuller H, Denning C: Exon skipping and gene transfer restore dystrophin expression in hiPSC-cardiomyocytes harbouring DMD mutations. Stem Cells and Development 2013. 22: 2714-24.
157. Klymiuk N, Blutke A, Graf A, Krause S…..**Aartsma-Rus A**….Wolf E: Dystrophin-deficient pigs provide new insights into the hierarchy of physiological derangements of dystrophic muscle. Hum Mol Genet 2013; 22: 4368-82.

158. Evers MM, Tran HD, Zalachoras I, Pepers BA, Meijer OC, den Dunnen JT, van Ommen GJ, **Aartsma-Rus A**, van Roon-Mom WM. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: Removal of the CAG containing exon. Neurobiol Dis. 2013; 58: 49-56.
159. Verhaart IEC, Tanganyika-de Winter CL, Karnaoukh TG, Kolfschoten IGM, de Kimpe SJ, van Deutekom JCT and **Aartsma-Rus A**: Dose-dependent pharmacokinetic profiles of 2'-O-methyl phosphorothioate antisense oligonucleotides in mdx mice. Nucleic Acids Therapeutics 2013; 23: 228-37.
160. Van Putten M, Hulsker M, Young C, Nadarajah VD, Heemskerk H, van der Weerd L, 't Hoen PAC, van Ommen GJB and **Aartsma-Rus A**: Low dystrophin levels increase survival and improve muscle pathology and function in dystrophin/utrophin double knockout mice. FASEB 2013; 27: 2484-95.
161. van Ommen GJ and **Aartsma-Rus A**: Advances in therapeutic RNA-targeting. N. Biotechnol. 2013 Jan 28. S1871-6784.
162. Tremblay JP, Xiao X, **Aartsma-Rus A,** Barbas C, Blau HM, Bogdanove AJ, Boycott K, Braun S, Breakefield XO, Bueren JA, Buschmann M, Byrne BJ, et al.: Translating the genomics revolution: the need for an international gene therapy consortium for monogenic diseases. Mol Ther. 2013; 21: 266-8.
163. McCormack P, Woods S, **Aartsma-Rus A**, Hagger L, Herczegfalvi A, Heslop E, Irwin J, Kirschner J, Moeschen P, Muntoni F, Ouillade MC, Rahbek J, Rehmann-Sutter C, Rouault F, Sejersen T, Vroom E, Straub V, Bushby K, Ferlini A: Guidance in social and ethical issues related to clinical, diagnostic care and novel therapies for hereditary neuromuscular rare diseases: "translating the translational". Plos Curr MD 2013, Jan 10, 5
164. Zalachoras I, Gootaers G, van Weert LT, Aubert Y, de Kreij SR, Datson NA, van Roon-Mom WM, **Aartsma-Rus A** and Meijer OC: Antisense-mediated isoform switching of steroid receptor coactivator-1 in the central nucleus of the amygdala of the mouse brain. BMC Neurosci. 2013; 14: 5
165. Yilmaz-Elis S, **Aartsma-Rus A,** Hoen PAC, Safdar H, Breukel C, van Vlijmen BJM, van Deutekom JCT, de Kimje SJ, van Ommen GJB and Verbeek SJ: IL-1 Signaling by Antisense Oligonucleotide Mediated Exon Skipping of IL-1 Receptor Accessory Protein (IL-1RAcP). Mol Ther NA 2013; 2: e66
166. Verhaart I and **Aartsma-Rus A**: The effect of 6-thioguanine on alternative splicing and antisense-mediated exon skipping treatment for Duchenne muscular dystrophy. Plos Curr MD 2012; Dec 12, 4
167. Lemmers RJ, Tawil R, Petek LM, Balog J, Block GJ….**Aartsma-Rus AM**…and van der Maarel SM: Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2. Nat Genet. 2012; 44: 1370-4.
168. Tanganyika-de Winter CL, Heemskerk H, Karnaoukh TG, van Putten M, de Kimpe SJ, van Deutekom JCT and **Aartsma-Rus A**: Long term exon skipping studies with 2'-O-methyl phosphorothioate antisense oligonucleotides in dystrophic mouse models. Mol Ther 2012; 1:e44.
169. Verhaart IEC and **Aartsma-Rus A**: Gene Therapy for Duchenne Muscular Dystrophy. Curr Opin Neurol 2012; 25:288-96.
170. Yilmaz-Elis S, **Aartsma-Rus A**, Vroon A, van Deutekom J, de Kimpe S, 't Hoen PA, van Ommen GJ, Verbeek JS: Antisense oligonucleotide mediated exon skipping as a potential strategy for the treatment of a variety of inflammatory diseases such as rheumatoid arthritis. Ann Rheum Dis 2012; 71 Suppl 2:i75-7.
171. Spitali P and **Aartsma-Rus A**: Progress in splice-modulating therapies for human disease. Cell 2012; 148: 1085-8
172. van Putten M, Hulsker MH, Nadaraja VD, van Heiningen SH, van Huizen E, van Iterson M, Admiraal P, Messemaker T, den Dunnen JT, 't Hoen PAC and **Aartsma-Rus A**: The effect of low levels of dystrophin on mouse muscle function and pathology. PLoS ONE 2012; 7: e31937
173. Van Putten M, Kumar D, Hulsker MH, Hoogaars WMH, Plomp JJ, van Opstal A, van Iterson M, Admiraal P, van Ommen GJB, 't Hoen PAC and **Aartsma-Rus A**: Comparison of skeletal muscle pathology and motor function of dystrophin and utrophin deficient mouse strains. Neuromuscul Dis 2012; 22: 406-17
174. Verhaart IE, van Duijn RJ, den Adel B, Roest AA, Verschuuren JJ, **Aartsma-Rus A** and van der Weerd L: Assessment of cardiac function in three mouse dystrophinopathies by magnetic resonance imaging. Neuromuscul Disord 2011; 22: 418-26
175. Kemaladewi DU, de Gorter DJ, **Aartsma-Rus A**, van Ommen GJ, Ten Dijke P, 't Hoen PA and Hoogaars WM: Cell-type specific regulation of myostatin signalling. FASEB J 2012; 26: 1462-72
176. Verhaart IE, Heemskerk H, Karnaoukh TG, Kolfschoten IG, Vroon A, van Ommen GJ, van Deutekom JC, **Aartsma-Rus A**: Prednisolone treatment does not interfere with 2'-O-methyl phosphorothioate antisense-mediated exon skipping in Duchenne

muscular dystrophy. Hum Gene Ther. 2012; 23:262-73.

177. 't Hoen PA, Jirka SM, Ten Broeke BR, Schultes EA, Aguilera B, Pang KH, Heemskerk H, **Aartsma-Rus A**, van Ommen GB and den Dunnen JT: Phage display screening without repetitious selection rounds. Anal Biochem 2011. 421: 622-31.
178. Anthony K, Cirak S, Torelli S, Tasca G, Feng L, Arechavala-Gomeza V, Armaroli A, Guglieri M, Straathof CS, Verschuuren JJ, **Aartsma-Rus A**, et al: Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials. Brain 2011; 134: 3544-56
179. Evers MM, Pepers BA, van Deutekom JCT, Mulders SA, den Dunnen JT, **Aartsma-Rus A**, van Ommen GJB and van Roon-Mom WCM: Targeting several CAG repeat expansion diseases by a single antisense oligonucleotide. PLoS One 2011; e24308
180. Zalachoras I, Evers MM, van Roon-Mom WCM, **Aartsma-Rus A** and Meijer OC: Antisense-mediated RNA targeting: versatile and expedient genetic manipulation in the brain. Front Mol Neurosci 2011; 4:10
181. Nadarajah VD, van Putten M, Chaouch A, Garrood P….**Aartsma-Rus A** et al: Serum Matrix Metalloproteinase-9 (MMP-9) as a biomarker for monitoring Duchenne Muscular Dystrophy (DMD) disease progression. Neuromuscul Disord 2011; 21: 569-78
182. Van Putten M and **Aartsma-Rus A**: Opportunities and challenges for the development of antisense treatment in neuromuscular disorders. Exp Opin Biol Ther 2011; 11: 1025-37
183. Kemaladewi DU, Hoogaars WM, van Heiningen SH, Terlouw S, de Gorter DJ, den Dunnen JT, van Ommen GJB, **Aartsma-Rus A**, ten Dijke P and 't Hoen PA: Dual exon skipping for myostatin and dystrophin for Duchenne muscular dystrophy. BMC Med Genomics 2011; 4: 36
184. Pichavant C, **Aartsma-Rus A**, Clemens PR, Davies KE, Dickson G, Takeda S, Wilton SD, Wolff JA, Wooddell CI, Xiao X and Tremblay JP: Current Status of Pharmaceutical and Genetic Therapeutic Approaches to Treat DMD. Mol Ther 2011; 19: 830-40
185. Goemans N, Tulinius M, van den Akker JT…..**Aartsma-Rus A**…and van Deutekom JCT: Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 2011; 364: 1513-22
186. **Aartsma-Rus A**, on behalf of the working group: Effects of long-term treatment and combination therapeutics for neuromuscular disorders. Report of a TREAT-NMD/NIH "Bringing down the barriers – Translational medicine in inherited neuromuscular diseases" conference working group. Neuromuscul Disord 2011; 21: 151-6.
187. **Aartsma-Rus A**, The risks of therapeutic misconception and n=1 "trials" in rare diseases. Requests for individual "trials" of exon skipping risk setting back the entire field. Neuromuscul Disord 2011; 21: 13-15.

Aartsma-Rus A, Response to a comment to this paper, Neuromuscul Disord 2011; 21: 527-8

188. **Aartsma-Rus A**, den Dunnen JT and van Ommen GJB: New insights in gene therapy: the example of Duchenne muscular dystrophy. Ann NY Acad Sci 2010; 1214:199-212.
189. Shi ST, Hoogaars WM, de Gorter DJ, van Heiningen SH, Lin HY, Hong CC, Kemaladewi DU, **Aartsma-Rus A**, Ten Dijke P and 't Hoen PA: BMP antagonists enhance myogenic differentiation and ameliorate the dystrophic phenotype in a DMD mouse model. Neurobiol Dis 2011; 41: 353-60
190. **Aartsma-Rus A**: Antisense-mediated modulation of splicing: Therapeutic implications for Duchenne muscular dystrophy. RNA Biology 2010; 7: 4
191. Spitali P, Heemskerk JA, Vossen RHAM, Ferlini A, den Dunnen JT, ,t Hoen PAC and **Aartsma-Rus A**: Accurate quantification of dystrophin mRNA and exon skipping levels in Duchenne muscular dystrophy. Lab Invest 2010; 90: 1396-402.
192. Heemskerk JA, de Winter CL, van Kuik P…**Aartsma-Rus A** and van Deutekom JCT: Pre-clinical PK and PD studies on 2'O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx Mouse model. Mol Ther 2010; 18: 1210-7.
193. **Aartsma-Rus A**, Houlleberghs H, van Deutekom JCT, van Ommen GJB and 't Hoen PAC: Exon-targeting antisense oligonucleotides outperform splice site targeting antisense oligonucleotides in the modulation of DMD splicing. Oligonucleotides 2010; 20: 69-77.
194. Muntoni F, Meeting Steering Committee and TREAT-NMD Network: The development of antisense oligonucleotides therapies for Duchenne muscular dystrophy: Report on a TREAT-NMD workshop hosted by the European Medicines Agency (EMA), on September 25th 2009. Neuromuscul Disord 2010; 20: 355-62.

195. Van Putten M, de Winter CL, van Roon-Mom W, van Ommen GJB, 't Hoen PAC and **Aartsma-Rus A**: A mild exercise regime does not affect disease parameters in the mdx mouse. Neuromuscul Disord 2010; 20: 273-80.
196. Helderman-van den Enden AT, Straathof CS, **Aartsma-Rus A**, den Dunnen JT, Verbist BM, Bakker E, Verschuuren JJ and Ginjaar HB: Becker muscular dystrophy patients with deletions around exon 51; A promising outlook for exon skipping therapy in Duchenne patients. Neuromuscul Disord 2010; 20: 251-4.
197. **Aartsma-Rus A**, Singh KH, Fokkema IF, Ginjaar IB, van Ommen GJ, Den Dunnen JT, van der Maarel SM: Therapeutic exon skipping for dysferlinopathies? Eur J Hum Genet 2010; 18: 889-94.
198. Popplewell LJ, Adkin C, Arechavala-Gomeza V, **Aartsma-rus A**, de Winter CL, Wilton SD, Morgan JE, Muntoni F, Graham IR, Dickson G: Comparative analysis of antisense oligonucleotides sequences targeting exon 53 of the human DMD gene; Implications for future clinical trials. Neuromuscul Disord 2010; 20: 102-110.
199. **Aartsma-Rus A** and van Ommen GJB: Progress in therapeutic antisense applications for neuromuscular disorders. Eur J Hum Gen 2010; 18: 146-53.
200. Heemskerk JA, de Winter CL, van Ommen GJB, van Deutekom JCT and **Aartsma-Rus A**: Development of antisense-mediated exon skipping as a treatment for Duchenne muscular dystrophy. Ann NY Acad Sc 2009; 1175: 71-9.
201. **Aartsma-Rus, A** and Van Ommen GJB: Less is more: therapeutic exon skipping for Duchenne muscular dystrophy. Lancet Neur 2009; 8: 873-5.
202. Van de Vosse E, Verhard EM, de Paus RA, ven Deutekom JCT, **Aartsma-Rus A** and van Dissel JT: Antisense-mediated exon skipping to correct IL12Rβ1 deficiency in T-cells. Blood 2009; 113: 4548-55.
203. **Aartsma-Rus A**, Fokkema I, Verschuuren JJ, Ginjaar HB, van Deutekom JCT, van Ommen GJB and den Dunnen JT: Applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat 2009; 30: 293-9.
204. Heemskerk JA, de Winter CL, de Kimpe SJ, van Kuik-Romeijn P, Heuvelmans N, Platenburg G, van Ommen GJB, van Deutekom JCT and **Aartsma-Rus A**: In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. J Gene Med 2009; 11: 257-66.
205. Van Vliet L, van Deutekom JCT, van Ommen GJB and **Aartsma-Rus A**: assessment of the feasibility of exon 45-55 multiexon skipping for Duchenne muscular dystrophy. BMC Med Genet 2008; 9: 105.
206. **Aartsma-Rus A**, van Vliet L, Hirschi M, Janson AM, Heemskerk JA, de Winter CL, de Kimpe SJ, van Deutekom JCT, 't Hoen PAC and van Ommen GJB: Guidelines for antisense oligonucleotide design and insight in splice modulating mechanisms. Mol Ther 2009; 17: 548-53.
207. Van Ommen GJB, van Deutekom JCT and **Aartsma-Rus A**: The therapeutic potential of antisense-mediated exon skipping. Curr Opin Mol Ther 2008; 10: 140-49.
208. Van Deutekom JCT, Janson AM, Ginjaar HB, **Aartsma-Rus A** et al: Local dystrophin restoration with antisense oligonucleotides PRO051. N Engl J Med 2007; 357: 2677-86.
209. Arechavala-Gomeza V, Graham IR, Popplewell LJ, Adams AM, **Aartsma-Rus A,** Kinali M, Morgan JE, van Deutekom JCT, Wilton SD, Dickson G and Muntoni F: Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle. Hum Gene Ther 2007; 18: 798-810.
210. **Aartsma-Rus A** and van Ommen GJB: Antisense-mediated exon skipping: A versatile tool with research and therapeutic applications. RNA 2007; 13: 1609-24.
211. **Aartsma-Rus A**, Janson AAM, van Ommen GJB, van Deutekom JCT: Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy. BMC Med Genet 2007; 8: 43.
212. **Aartsma-Rus A**, Janson AAM, Heemskerk JA, de Winter CL, van Ommen GJB and van Deutekom JCT: Therapeutic modulation of DMD splicing by blocking exonic splicing enhancer sites with antisense oligonucleotides. Ann NY Acad Sc 2006; 1082: 74-6.
213. White SJ, **Aartsma-Rus A**, Flanigan KM, Weiss RB, Kneppers ALJ, Lalic T, Janson AAM, Ginjaar HB, Breuning MH and den Dunnen JT: Duplications in the DMD gene. Hum Mutat 2006; 27: 938-45.
214. 't Hoen PAC, van der Wees CGC, **Aartsma-Rus A**, Turk R, Goyenvalle A, Danos O, Garcia L, van Ommen GJB, den Dunnen JT and van Deutekom JCT: Gene expression profiling to monitor therapeutic and adverse effects of antisense therapies for Duchenne muscular dystrophy. Pharmacogenomics 2006; 7: 281-97.
215. **Aartsma-Rus A**, van Deutekom JCT, Fokkema IF, van Ommen GJC, den Dunnen JT: Entries in the Leiden DMD mutation

database: An overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve 2006; 34: 135-44.

216. **Aartsma-Rus A**, Kaman WE, Weij R, den Dunnen JT, van Ommen GJB and van Deutekom JCT: Exploring the frontiers of therapeutic exon skipping for Duchenne muscular dystrophy by double targeting within one or multiple exons. Mol Ther 2006; 12: 401-7.
217. **Aartsma-Rus A**, de Winter CL, Janson AAM, Kamen WE, van Ommen GJB, den Dunnen JT and van Deutekom JCT: Functional analysis of 114 exon-internal AONs for targeted DMD exon skipping: Indication for steric hindrance of SR protein binding sites. Oligonucleotides 2005; 15: 285-97.
218. Bremmer-Bout M, **Aartsma-Rus A**, de Meijer EJ, Kaman WE, Janson A, Vossen R, van Ommen GJB, den Dunnen JT and van Deutekom JCT: Targeted exon skipping in transgenic hDMD mice: A model for direct pre-clinical screening of human-specific antisense oligonucleotides. Mol Ther 2004; 10: 232-40.
219. **Aartsma-Rus A**, Janson AA, Kaman WE, Bremmer-Bout M, van Ommen GJ, den Dunnen JT and van Deutekom JCT: Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense. Am J Hum Genet 2004; 74: 83-92.
220. **Aartsma-Rus A**, Kamen WE, Bremmer-Bout M, Janson A, Den Dunnen JT, van Ommen GJB and van Deutekom JCT: Comparative analysis of antisense oligonucleotides analogs for targeted DMD exon 46 skipping in muscle cells. Gene Ther 2004; 11: 1391-98.
221. **Aartsma-Rus A**, Janson AA, Kaman WE, Bremmer-Bout M, den Dunnen JT, Baas F, van Ommen GJ and van Deutekom JCT: Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum Mol Genetc 2003; 12: 907-14.
222. **Aartsma-Rus A**, Bremmer-Bout M, Janson A, Den Dunnen J, van Ommen GJB and van Deutekom JCT: Targeted exon skipping as a potential gene correction therapy for Duchenne muscular Dystrophy. Neuromuscul Disord 2002; 12: S71-77.

Other publications

1. Van Putten M and **Aartsma-Rus A**: Gene therapy for Duchenne muscular dystrophy. eLS (Wiley's online reference network) 2013.
2. Verhaart IEC and **Aartsma-Rus A**: Therapeutic approaches in development for Duchenne muscular dystrophy 2011; Journal for Neurology and Psychiatry of Child and Adolescent in Romania. ISSN 2068-8040. (Also translated into Romanian)
3. De Winter CL and **Aartsma-Rus A**: RNA-therapie voor de ziekte van Duchenne, Minder is meer. Analyse 2007; 07: 192-196. (Winner of the Anna Wichersprijs for best paper in 2007-2008)
4. Van den Bergen J, Straathof C, **Aartsma-Rus A**, Ginjaar HB et al: Onderzoek en zorg bij Duchenne spierdystrofie. Nederlands Tijdschrift van Geneeskunde 2009; 153:B298

Book chapters

1. Daoutsali E, **Aartsma-Rus A**. Splicing modulation for therapeutics, in Advances in Nucleic Acid Therapies 2019; (Ed. Gait M, Agrawal S); Royal Society of Chemistry Press
2. Hiller M, Spitali P, Datson N, **Aartsma-Rus A**. Exon 51 Skipping Quantification by Digital Droplet PCR in del52hDMD/mdx Mice. Methods Mol Biol.2018;1828:249-262
3. **Aartsma-Rus A**, van Ommen GJB and Kaplan JC. (2013). Innovating therapies for muscle diseases. In Pediatric Neurology; Handbook of Clinical Neurology 3rd series (Ed. Dulac O., Lassonde M and Sarnat H) Elsevier, Chennai India. 113:1497-501.
4. Verhaart I & **Aartsma-Rus A** (2012) AON-mediated exon skipping for Duchenne muscular dystrophy. In Neuromuscular Disease (Ed Ashraf Zaher) Intech.
5. Spitali P & **Aartsma-Rus A** (2012) Duchenne muscular dystrophy: therapeutic approaches to restore dystrophin. In Muscular Disorders (Ed Madhuri Hedge) Intech.
6. Van Roon WCM & **Aartsma-Rus A** (2011) Overview on antisense-mediated exon skipping. In Methods of exon skipping, Methods in Molecular Biology (Ed Aartsma-Rus A) Humana Press, Springer New York Dordrecht Heidelberg London.
7. **Aartsma-Rus A** (2011) Antisense-mediated exon skipping for Duchenne muscular dystrophy. In Methods of exon skipping, Methods in Molecular Biology (Ed Aartsma-Rus A) Humana Press, Springer New York Dordrecht Heidelberg London.

8. **Aartsma-Rus A** (2011) Overview on AON design. In Methods of exon skipping, Methods in Molecular Biology (Ed Aartsma-Rus A) Humana Press, Springer New York Dordrecht Heidelberg London.
9. **Aartsma-Rus A** & van Ommen GJB. (2010) Antisense-mediated exon skipping for Duchenne muscular dystrophy. In Muscle Gene Therapy (Ed Duan, D) Springer New York Dordrecht Heidelberg London.
10. **Aartsma-Rus A** and van Deutekom JCT et al. (2009). Oligonucleotides to modulate splicing. In Methods of alternative splicing (Ed Stamm S) EURASNET Network of Excellence.
11. **Aartsma-Rus A** and van Deutekom JCT (2008): Antisense-Mediated Reading-Frame Restoration as a Genetic Therapy for Duchenne Muscular Dystrophy. In Antisense Elements (Genetics) (Ed Hernandes, A.G.) Novapublishers, Hauppauge, NY.

ProjectsMembershipsOther Relevant Information